Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

New England Journal of Medicine - Tập 380 Số 12 - Trang 1116-1127 - 2019
Brian I. Rini1, Elizabeth R. Plimack2, V.P. Stus3, Rustem Gafanov4, Robert Hawkins5, Dmitry Nosov6, Frédéric Pouliot7, B. Yа. Alekseev8, Denis Soulières9, Bohuslav Melichar10, Ihor Vynnychenko11, Anna Kryzhanivska12, Igor Bondarenko13, Sérgio Jobim Azevedo14, Delphine Borchiellini15, Cezary Szczylik16, Maurice Markus17, Ray McDermott18, Jens Bedke19, Sophie Tartas20, Yen‐Hwa Chang21, Satoshi Tamada22, Qiong Shou23, Rodolfo F. Perini24, Chen Mei24, Michael B. Atkins25, Thomas Powles26
1Cleveland Clinic, Taussig Cancer Institute, Cleveland
2Fox Chase Cancer Center, Philadelphia
3Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine
4Russian Scientific Center of Roentgen Radiology, Moscow
5Christie NHS Foundation Trust, Manchester
6Central Clinical Hospital with Outpatient Clinic, Moscow
7de Québec and Université Laval, Quebec, QC
8Hertzen Moscow Cancer Research Institute, Moscow
9CHU de Montréal, Montreal
10Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic
11Dnipro, Sumy State University, Sumy Regional Oncology Center, Sumy
12Ivano-Frankivsk National Medical University, Ivano-Frankivsk
13Dnipropetrovsk Medical Academy
14Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
15Centre Antoine Lacassagne, Université Côte d’Azur, Nice
16Military Institute of Medicine, Warsaw, Poland
17Rocky Mountain Cancer Center, Colorado Springs, CO
18Adelaide and Meath Hospital and University College Dublin, Dublin
19Department of Urology, Eberhard-Karls University Tübingen, Tübingen, Germany
20Hôpitaux Universitaires de Lyon, Lyon
21Taipei Veterans General Hospital, Taipei, Taiwan
22Osaka City University Hospital, Osaka, Japan
23MSD China, Beijing
24Merck, Kenilworth, NJ
25Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
26Barts Health and the Royal Free NHS Trusts, Barts Cancer Institute, and Queen Mary University of London, London

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1056/NEJMra1601333

10.1016/S0140-6736(07)61904-7

10.1200/JCO.2008.20.1293

10.1200/JCO.2009.26.5561

10.1016/j.ejca.2012.12.010

10.1016/S1470-2045(13)70465-0

10.1056/NEJMc1400731

10.1016/j.clgc.2017.07.017

10.1200/JCO.2018.36.15_suppl.4500

10.1016/S1470-2045(18)30081-0

10.1200/JCO.1984.2.3.187

10.1016/j.ejca.2008.10.026

10.1200/JCO.2008.21.4809

10.1200/JCO.2008.19.3342

10.1056/NEJMoa1712126

10.1200/JCO.2018.36.6_suppl.578

KEYTRUDA (pembrolizumab) for injection, for intravenous use. Whitehouse Station, NJ: Merck, 2018 (prescribing information) (https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf).

INLYTA (axitinib) tablets for oral administration. New York: Pfizer, 2018 (prescribing information) (http://labeling.pfizer.com/ShowLabeling.aspx?id=759).

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 380 Số 12

1116-1127

Thông tin tác giả